Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.64 |
| ▸ | GAPDH | P04406 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.64 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16801790 | 1.00 | ADORA1 (0.67) | ADORA1ADORA3ADORA2BDPP4MEN1 | |
| SCHEMBL2402159 | 1.00 | ADORA1 (0.67) | ADORA1ADORA3ADORA2BDPP4MEN1 | |
| SCHEMBL2524242 | 0.92 | ADORA1 (0.66) | ADORA1ADORA3ADORA2BDPP4MEN1 | |
| SCHEMBL2524241 | 0.92 | ADORA1 (0.66) | ADORA1ADORA3ADORA2BDPP4MEN1 | |
| SCHEMBL24943491 | 0.88 | ADORA1 (0.62) | ADORA1ADORA3ADORA2BDPP4MEN1 | |
| SCHEMBL16002755 | 0.88 | ADORA2A (0.57) | ADORA1ADORA3ADORA2BADORA2AHIF1A | |
| SCHEMBL18950667 | 0.88 | ADORA2A (0.57) | ADORA1ADORA3ADORA2BADORA2AHIF1A | |
| SCHEMBL18349680 | 0.87 | ADORA1 (0.63) | ADORA1ADORA3ADORA2BDPP4MEN1 | |
| SCHEMBL16392751 | 0.87 | ADORA1 (0.63) | ADORA1ADORA3ADORA2BDPP4MEN1 | |
| SCHEMBL16392739 | 0.87 | ADORA1 (0.63) | ADORA1ADORA3ADORA2BDPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912989-B2 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11912989-B2 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20230279099-A1 | TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230279099-A1 | TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-07 | — | — | US | disclosed |
| US-11673947-B2 | Target tissue-specific antigen-binding molecule | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673947-B2 | Target tissue-specific antigen-binding molecule | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-06-13 | — | — | US | disclosed |
| US-20210180049-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10961530-B2 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-30 | — | — | US | disclosed |
| US-20160304862-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160304862-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20150166654-A1 | TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166654-A1 | TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-18 | — | — | US | disclosed |
| WO-2013180200-A1 | TARGET-TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | 中外製薬株式会社 (JP) | 2013-12-05 | — | — | WO | disclosed |
| US-8026349-B2 | Polynucleotide synthesis labeling chemistry | DHARMACON, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | DHARMACON, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166654-A1 | TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | CD74, MICA, LY96 | ADORA1 4410/4885ADORA3 4367/4885ADORA2B 4315/4885 |
| US-20210180049-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | MICA, CD69, CD74 | ADORA1 2281/4885ADORA3 2649/4885ADORA2B 2951/4885 |
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | POLN, POLRMT, POLM | ADORA1 2390/4885ADORA3 1772/4885ADORA2B 2431/4885 |
| US-11673947-B2 | Target tissue-specific antigen-binding molecule | CD74, LY96, CD2BP2 | ADORA1 4366/4885ADORA3 4222/4885ADORA2B 4290/4885 |
| US-20230279099-A1 | TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | CD74, LY96, CD2BP2 | ADORA1 4366/4885ADORA3 4222/4885ADORA2B 4290/4885 |
| US-11912989-B2 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules | MICA, CD69, CD74 | ADORA1 2281/4885ADORA3 2649/4885ADORA2B 2951/4885 |
| US-20160304862-A1 | ANTIGEN-BINDING MOLECULES, THE ANTIGEN-BINDING ACTIVITY OF WHICH VARIES ACCORDING TO THE CONCENTRATION OF COMPOUNDS, AND LIBRARIES OF SAID MOLECULES | MICA, CD69, CD74 | ADORA1 2281/4885ADORA3 2649/4885ADORA2B 2951/4885 |
| US-10961530-B2 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules | MICA, CD69, CD74 | ADORA1 2281/4885ADORA3 2649/4885ADORA2B 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.